EXACT SCIENCES CORP
EXASExact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How EXAS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Modified FOLFIRINOX | Phase 2 | Locally Advanced Pancreatic Adenocarcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in EXACT SCIENCES CORP's drug pipeline?→
CatalystAlert tracks 1 drug candidate in EXACT SCIENCES CORP's (EXAS) pipeline across Phase 2. Its lead program is Modified FOLFIRINOX (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EXACT SCIENCES CORP's next FDA catalyst?→
EXACT SCIENCES CORP's (EXAS) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EXAS biotech catalysts?→
Add EXAS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EXACT SCIENCES CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.